ScreenerHero

OSUROraSure Technologies, Inc.

NAS · US · Healthcare · Medical Instruments & Supplies · orasure.com
3.880USD+4.86%Mkt Cap: 267.60M $P/E: —

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internatio…

Industry Peers

Medical Instruments & Supplies
Screen all
ISRG
Intuitive Surgical, Inc.
$135.72BUSDP/E 43.4
EL
EssilorLuxottica Societe anonyme
$81.53BUSDP/E 30.5
BDX
Becton, Dickinson and Company
$52.30BUSDP/E 33.2
MDLN
Medline Inc. Class A Common Stock
$46.09BUSDP/E 42.8
ALC
Alcon AG
$35.59BUSDP/E 56.2
ALC
Alcon AG
$32.44BUSDP/E 55.0
RMD
ResMed Inc.
$33.40BUSDP/E 22.2
WST
West Pharmaceutical Services, Inc.
$24.85BUSDP/E 45.2
DIM
Sartorius Stedim Biotech
$20.46BUSDP/E 64.5
SRT3
Sartorius Aktiengesellschaft
$18.52BUSDP/E 86.9
STMN
Straumann Holding AG
$16.89BUSDP/E 40.2
SRT
Sartorius Aktiengesellschaft
$14.73BUSDP/E 69.1
SOLV
Solventum Corporation Common Stock
$15.25BUSDP/E 10.9
COO
The Cooper Companies, Inc.
$14.87BUSDP/E 64.6
BAX
Baxter International Inc.
$13.62BUSD
ALGN
Align Technology, Inc.
$11.55BUSDP/E 27.6
RGEN
Repligen Corporation
$10.22BUSDP/E 244.8
AVTR
Avantor, Inc.
$9.78BUSD
ATR
AptarGroup, Inc.
$8.57BUSDP/E 24.3
YPSN
Ypsomed Holding AG
$6.08BUSDP/E 24.8
HeadlineSourceTime
Older
OraSure (OSUR) Q2 2026 Earnings Call Transcript

Revenue beat guidance at $30.6M, but IntelliQ CT/NG FDA clearance delayed to 2027.

Motley Fool
OraSure Technologies, Inc. Q2 2026 Earnings Call Summary

Moby summary of OraSure Technologies, Inc.'s Q2 2026 earnings call

Moby
OraSure Technologies Inc (OSUR) (Q2 2026) Earnings Call Highlights: Revenue Surges 9. ...

OraSure exceeds Q2 guidance with strong growth in diagnostics and sample management, while navigating regulatory delays and maintaining a robust cash position.

GuruFocus.com
OraSure Technologies Q2 Earnings Call Highlights

OraSure Technologies (NASDAQ:OSUR) reported second-quarter revenue of $30.6 million, exceeding its guidance range and rising 9.7% sequentially, as stronger public-health diagnostics demand and growth in sample-management products supported results. President and Chief Executive Officer Carrie Eglin

MarketBeat
Is Co-Diagnostics National Security’s Next Diagnostic Pick?
MarketBeat